Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) EBITDA (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed EBITDA for 6 consecutive years, with -$17.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA fell 1740.58% year-over-year to -$17.5 million, compared with a TTM value of -$76.3 million through Sep 2025, down 80.44%, and an annual FY2024 reading of -$63.7 million, down 0.69% over the prior year.
  • EBITDA was -$17.5 million for Q3 2025 at Barinthus Biotherapeutics, down from -$12.8 million in the prior quarter.
  • Across five years, EBITDA topped out at $13.2 million in Q2 2022 and bottomed at -$31.0 million in Q4 2024.
  • Average EBITDA over 5 years is -$11.7 million, with a median of -$15.0 million recorded in 2025.
  • The sharpest move saw EBITDA surged 230.71% in 2022, then tumbled 2180.43% in 2023.
  • Year by year, EBITDA stood at -$16.7 million in 2021, then tumbled by 50.55% to -$25.1 million in 2022, then surged by 62.13% to -$9.5 million in 2023, then crashed by 225.7% to -$31.0 million in 2024, then surged by 43.44% to -$17.5 million in 2025.
  • Business Quant data shows EBITDA for BRNS at -$17.5 million in Q3 2025, -$12.8 million in Q2 2025, and -$15.0 million in Q1 2025.